Molecular characterization and antimicrobial susceptibility profiles in Streptococcus agalactiae colonizing strains: association of erythromycin resistance with subtype III-1 genetic clone family  by Florindo, C. et al.
Molecular characterization and antimicrobial susceptibility proﬁles in
Streptococcus agalactiae colonizing strains: association of erythromycin
resistance with subtype III-1 genetic clone family
C. Florindo1, S. Viegas1, A. Paulino1, E. Rodrigues2, J. P. Gomes1 and M. J. Borrego1
1) Department of Infectious Diseases and 2) Department of Epidemiology, National Institute of Health, Lisbon, Portugal
Abstract
Knowledge of the epidemiology of Streptococcus agalactiae in Portugal is limited: therefore, the present study aimed to investigate the
carriage rate of S. agalactiae among Portuguese women of reproductive age and the prevalence of antibiotic resistance, as well as to
perform a molecular characterization of the clinical isolates. S. agalactiae was recovered from 6.2% of 4269 women during the period
2005–2007, with a predominance of capsular genotypes III (35%), V (33%), Ia (16%) and II (10%) in a sample of 100 isolates. To our
knowledge, this is the ﬁrst report of the S. agalactiae colonization rate in Portugal determined according to CDC guidelines. All isolates
were susceptible to penicillin and vancomycin, whereas resistance to clindamycin and erythromycin was detected in 10% and 19% of iso-
lates, respectively. Among the 19 erythromycin-resistant isolates, ten (53%) displayed the constitutive MLSB phenotype (conferring high-
level resistance to macrolides), eight (42%) had the inducible MLSB, and the M phenotype accounted for one isolate (5%). erm methylase
genes were exclusively associated with MLSB phenotype isolates, whereas the M phenotype was a result of the presence of mefA.
Multilocus sequence typing analysis of the genetic relatedness among isolates presenting resistance to erythromycin demonstrated a
novel association between erythromycin resistance and the subtype III-1/ST-19 genetic clone family.
Keywords: Antibiotic resistance, capsular genotyping, MLST, Portugal, Streptococcus agalactiae
Original Submission: 21 August 2009; Revised Submission: 9 October 2009; Accepted: 22 October 2010
Editor: D. Raoult
Article published online: 2 November 2009
Clin Microbiol Infect 2010; 16: 1458–1463
10.1111/j.1469-0691.2010.03106.x
Corresponding author: M. J. Borrego, National Institute of Health,
Av. Padre Cruz, 1649-016 Lisbon, Portugal
E-mail: m.jose.borrego@insa.min-saude.pt
Introduction
Streptococcus agalactiae is a commensal bacterium of the
human gastrointestinal and genital tracts [1] and recent stud-
ies have reported asymptomatic colonization rates of up to
36% in healthy women [2–5]. Moreover, it represents a
major cause of bacterial infections in newborns [1]. Penicillin
is the antibiotic of choice for the prophylaxis and treatment
of S. agalactiae infections. However, there are many penicil-
lin-allergic individuals who require the use of second-line
antibiotics [6] to which a resistance increase has been
described in several countries [7–9]. Streptococcal resistance
to macrolides is commonly mediated by two major mecha-
nisms [10]: (i) the effects on the macrolide-speciﬁc efﬂux
mechanism (M phenotype), encoded by the mefA gene, and
(ii) modiﬁcation of the antibiotic binding site of 23S rRNA
methylases, encoded by the erm genes (MLSB phenotype),
which can be either inducible (iMLSB) or constitutive
(cMLSB).
The most common classiﬁcation of S. agalactiae strains is
based on the capsular polysaccharide, deﬁning nine recog-
nized capsular serotypes (Ia, Ib, II–VIII) among which the
most common are Ia, II, III and V (accounting for 80% or
more in the USA and Western Europe) [11].
Multilocus sequence typing (MLST), has been used for the
evaluation of the S. agalactiae population structure, genetic
lineages and, most of all, for the investigation of virulence
potential and tropism [12].
In the present study, we aimed to: (i) evaluate the S. aga-
lactiae colonization rate among women of reproductive age
living in the Lisbon metropolitan area (because maternal
S. agalactiae colonization is a major risk factor for early-onset
neonatal disease); (ii) deﬁne the capsular genotype distribu-
tion; (iii) determine the prevalence of antibiotic resistance in
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S. agalactiae and its mechanisms; and (iv) identify the genetic
lineages among the antibiotic-resistant S. agalactiae clones.
Clariﬁcation of these issues is important for understanding




Between January 2005 and December 2007, 4269 women of
reproductive age (15–49 years) of which 1310 were preg-
nant, and attending general practice, gynaecology and family
planning clinics located in the Lisbon area, were screened for
S. agalactiae colonization at the National Institute of Health
in Lisbon. In accordance with the CDC guidelines [6], sepa-
rate lower vaginal and rectal swabs were collected and both
swabs were placed in a single tube containing Todd-Hewitt
selective enrichment broth (bioMe´rieux, Marcy l’Etoile,
France). Subcultures on 5% sheep-blood agar plates were
performed, and S. agalactiae strains were identiﬁed by stan-
dard criteria on the basis of colony morphology, Gram stain-
ing, nonhydrolysis of aesculin on bile-aesculin agar and group
B latex-agglutination assay (Becton Dickinson, Sparks, USA).
Budget constraints prevented extensive molecular charac-
terization (at least eight loci for each bacterial isolate) and
antibiotic susceptibility testing of all S. agalactiae isolates.
Therefore, a sample of 100 isolates, comprising the ﬁrst 34,
33 and 33 isolates from 2005, 2006 and 2007, respectively,
was adopted (see Statistical analysis).
Antimicrobial susceptibility testing and macrolide resistance
phenotypes
MICs were determined by E-test (AB Biodisk, Solna,
Sweden). Each strain was tested for its susceptibility to four
antibiotics (penicillin G, erythromycin, clindamycin and
vancomycin), in accordance with the CLSI guidelines [13].
The constitutive, inducible and M resistance phenotypes
were identiﬁed by the double-disc diffusion method, as
described previously [7].
The presence of the resistance genes ermTR, ermB and
mefA was also investigated. In brief, total S. agalactiae DNA
was isolated by using the QIAamp DNA mini kit (Qiagen,
Valencia, CA, USA) in accordance with the manufacturer’s
instructions, and was subsequently ampliﬁed through previ-
ously reported primers (Table 1) and the multiplex PCR
technique [9,14]. Brieﬂy, the PCR reaction used 1 · optibuf-
fer (Bioline, London, UK), 0.2 mM dNTPs (Bioline), 2.8 mM
MgCl2, 25 pmol of each primer (MGW Biotech, Ebersberg,
Germany), 1.5 U of bio-x-act DNA polymerase (Bioline) and
5 lL of template for a ﬁnal reaction volume of 25 lL. The
thermocycling proﬁle consisted of an initial denaturation step
at 95C for 5 min, followed by 35 cycles at 95C for 30 s,
56C for 30 s and 70C for 50 s. The ﬁnal extension step
consisted of 10 min at 70C.
Capsular genotyping and MLST
The S. agalactiae isolates were subjected to capsule genotyp-
ing by a method previously described by Kong et al. [15]
with some modiﬁcations. New PCR primers (Table 1) were
designed based on capsular polysaccharide synthesis D, E and
F gene cluster from S. agalactiae reference strains of geno-
types Ia, Ib and II to VII [15]. For clariﬁcation purposes, and
because we used DNA-based typing methods (as is most
common among recent S. agalactiae studies), capsular types
are designated as genotypes throughout the text, instead of
serotypes. PCR reagents and thermocycling proﬁles were
the same as above, except for the annealing temperature
(51C), and extension step (2 min for 20 s at 68 C). Puri-
ﬁed amplicons were sequenced using the ABI Prism 3700
DNA sequencer (Applied Biosystems, Foster City, CA, USA)
(for ampliﬁcation primers and internal primer, see Table 1).
TABLE 1. Oligonucleotide primers
used for PCR and sequencing Locus Primer Sequence (5¢ to 3¢)
Amplicon
size (bp)
ermB ermB-1 GAAAAGGTACTCAACCAAATA (upper) 639
ermB-2 AGTAACGGTACTTAAATTGTTTAC (lower)
ermTR ermTR-1 GAAGTTTAGCTTTCCTAA (upper) 395
ermTR-2 GCTTCAGCACCTGTCTTAATTGAT (lower)
mefA mefA-1 AGTATCATTAATCACTAGTGC (upper) 346
mefA-2 TTCTTCTGGTACTAAAAGTGG (lower)
16S rRNA 16S-1 GGAGGAAGGTGGGGATGACG (upper) 241
16S-2 ATGGTGTGACGGGCGGTGTG (lower)
cpsDa cpsD-1 GTTGTTGATGCCGCAATAATC (upper) 1902 or 1911
cpsFa cpsF-1 CTACAGCGGCACCAGATGATA (lower)
cpsEb cpsE-1 TCTTACGCTAAGTTTTCACG
aPCR primers also used for automated sequencing.
bPrimer only used for automated sequencing
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Nucleotide sequences of 1625 or 1634 bp, within the
approximately 1.9 kb amplicon (positions 565–2189 bp from
start codon of cpsD, relative to the genome sequence of
S. agalactiae strain 2603V/R (GenBank accession number
AE009948)) were aligned through Lasergene99 software
(DNASTAR, Madison, WI, USA) with GenBank available
cpsD-cpsE-cpsF sequences of S. agalactiae reference
strains (GenBank accession numbers AF332893 for Ia/
090, AF332894 for Ia/NCDC SS615, AF332903 for Ib/H36B,
AF332905 for II/18RS21, AF332900 for III-1/GB00-009, AF332896
for III-2/M781, AF332897 for III-3/NCDCSS620, AF381030
for III-4/WC3935, AF332908 for IV/3139, AF332910 for
V/CJB111, AE009948 for V/2603V-R, AF349539 for
V/CNCTC 1-82, AF337958 for VI/NT6 and AF332913
for VII/7271) aiming to identify the capsular type and/or sub-
type (Ia, Ib, II, III-1, III-2, III-3, III-4 and IV to VII) of each
S. agalactiae isolate. Except for serotype VIII and IX, this
modiﬁed methodology allowed total discrimination between
the S. agalactiae genotypes and subtypes of genotype III, as
against the 790-bp region described by Kong et al. [15].
The MLST analysis of macrolide-resistant strains was per-
formed as described previously [12]. Alleles for the seven
loci were analysed on the MLST website (http://sagalactiae.
mlst.net), and the combination of these results provided an
allelic proﬁle or sequence type (ST). eBURSTV3 software
(http://eburst.mlst.net) was used to deﬁne relationships
between STs.
Statistical analysis
For the capsular genotyping, MLST analysis, and the antimi-
crobial susceptibility evaluation, the sample size was set at
100 strains, considering an expected macrolide resistance of
approximately 18% (based on a previous epidemiological
evaluation performed in Lisbon) [16] for 95% CI with 6%
precision for a ﬁnite population.
Associations between categorical variables were calculated
using the Fisher’s exact test with a signiﬁcance level of 5%.
All presented statistical results were obtained using SPSS,
version 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Among the 4269 women of reproductive age, 263 (6.2%)
were culture positive for S. agalactiae. Similar anogenital
S. agalactiae colonization rates were observed among non-
pregnant (181/2959; 6.1%) and pregnant women (82/1310;
6.3%), as described previously [2].
The 100 randomly selected isolates were fully typeable
and belonged to genotypes I to V, with predominance of
genotypes Ia, II, III and V, which together represented 94%
of all isolates (Table 2).
No S. agalactiae isolate showed resistance to penicillin G
(MIC 0.032–0.125 mg/L) or vancomycin (MIC 0.25–1 mg/L).
Erythromycin resistance, however, was identiﬁed in 19% of
strains (n = 19), whereas ten of these were also resistant to
clindamycin (Table 2). Regarding the resistance mechanisms
of the 19 macrolide-resistant strains, ten displayed the con-
stitutive MLSB phenotype, eight the inducible MLSB pheno-
type, and one the M phenotype (for which the MICs of
erythromycin and clindamycin were 4 and 0.064 mg/L,
respectively). With the multiplex PCR assay, it was possible
to test for the presence of the genes responsible for the
macrolide resistance phenotypes (Table 2). Each screened























lineages (STs)bermB ermTR mefA
Ia 16 0 0 1 (6.2) 1 (6.2) 1 0 0 ST-23 (n = 1)
Ib 3 0 0 1 (33.3) 1 (33.3) 1 0 0 ST-8 (n = 1)
II 10 0 0 0 0 – – – –
III 35 7 (20) 0 6 (17.1) 13 (37.1) – – – –
III-1c 22 7 (31.8) 0 5 (22.7) 12 (54.5) 4 6d 1 ST-19 (n = 7); ST-27 (n = 1);
ST-44 (n = 1); ST-106 (n = 2);
ST-369 (n = 1)
III-2 13 0 0 1 (7.7) 1 (7.7) 1 0 0 ST-17 (n = 1)
IV 3 0 0 0 0 – – – –
V 33 2 (6) 0 2 (6) 4 (12) 2 2 0 ST-1 (n = 1); ST-2 (n = 2);
ST-10 (n = 1)
aNone of the strains carried more than one resistance gene.
bRefers to the 19 erythromycin-resistant S. agalactiae strains.
cOne strain did not harbour any of the three resistance genes.
dOne strain showed the constitutive MLSB phenotype.
MLST, multilocus sequence typing.
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strain presented only a single resistance gene. As expected,
S. agalactiae strains presenting the cMLSB phenotype were
highly resistant to erythromycin and clindamycin (MICs ‡
256 mg/L) because of the presence of the ermB gene. One
exception occurred, where a highly resistant strain presented
the ermTR gene. By contrast, almost all of the iMLSB resis-
tance phenotypes were conferred by the presence of the
ermTR gene. An exception occurred for one erythromycin-
resistant strain (MIC 2 mg/L), which exhibited the iMLSB
phenotype but did not yield any PCR product. The occur-
rence of inhibition was improbable because the ampliﬁcation
of the internal control was observed. As expected, the mefA
gene was identiﬁed in the single S. agalactiae strain displaying
the drug efﬂux mechanism.
The data obtained in the present study revealed that mac-
rolide resistance was not equally distributed among the
S. agalactiae genotypes (Table 2). Indeed, S. agalactiae strains
expressing the capsular genotypes III or V accounted for a
higher proportion of the erythromycin-resistant strains (17
of 19; 90%), followed by genotypes Ia and Ib (one strain
each). Furthermore, we observed that 12 of the 13 resistant
strains expressing genotype III belonged to capsular subtype
III-1 (v2 test, p <0.001), where 50% of these displayed the er-
mTR gene, reﬂecting macrolide resistance and susceptibility
to lincosamides (Table 2). The other two resistance genes
were also found in the strains with subtype III-1. One III-1
strain did not harbour any of the three resistance genes.
MLST analysis of 19 macrolide-resistant strains demon-
strated the existence of different genetic lineages, including
among strains expressing the same capsular genotype
(Table 2). In particular, we identiﬁed ﬁve distinct STs (ST-19,
ST-27, ST-44, ST-106 and ST-369) among the strains with
subtype III-1 (n = 12), although the majority presented the
ST-19 genetic lineage (n = 7). Despite the high number of
STs, strains expressing subtype III-1 were clustered together
in the same eBURST group (Fig. 1), which only corresponds
to part of the clonal complex 19 (CC19); this phenomenon
may be a result of the limited number of strains that were
studied (http://sagalactiae.mlst.net). Thus, the majority of ST’s
were single-locus or double-locus variants of each other,
constituting a clonal cluster represented by ST-19 and associ-
ated ST’s.
Discussion
In Portugal, antenatal screening for S. agalactiae in routine
clinical settings often reveals substantial discrepancies from
the CDC guidelines. Because maternal colonization is the
most important risk factor for invasive S. agalactiae neonatal
disease, and because a previous Portuguese study reported
6.6% mortality in S. agalactiae infections of newborns [17],
we aimed to determine the streptococcal colonization rate
among women of reproductive age according to CDC guide-
lines. The colonization rate obtained (6.2%) was low com-
pared to a recent Portuguese study (20%) [18]; this could be
explained by the application of different experimental meth-
odologies. The results obtained in the present study are in
accordance with the low prevalence rates described for
some Southern European countries, namely Greece (6.6%)
and Turkey (6.5%) and in contrast to the high rates
described in Scandinavia (25.4–36%) [3,5,19,20].
The capsular cps-based genotyping identiﬁed several
S. agalactiae types. Genotypes III (35%), V (33%), Ia (16%)
and II (10%) were the most common, contrasting with the
low prevalence of genotypes Ib and IV (3% each). The S. aga-
lactiae capsular distribution was similar to that previously
described in Lisbon (1999–2002, vaginal strains) [16] and
these apparently have been the most successful capsular
genotypes in the Lisbon metropolitan area in last decade.
However, S. agalactiae capsular typing in other studies dem-
onstrated the predominance of other genotypes (IV in Uni-
ted Arab Emirates and VI–VIII in Japan) [21,22]; this could
reﬂect speciﬁcities of immune responses which may vary
according to the studied population.
The recent emergence of S. agalactiae strains with
reduced penicillin susceptibility in Japan and the USA consti-
tutes a major threat to the use of penicillin in prophylaxis
[23,24]. The molecular characterization of those strains
revealed a mutagenic pathway similar to that observed a few






FIG. 1 eBURST diagram of the genetic lineages among erythromy-
cin-resistant Streptococcus agalactiae strains belonging to subtype III-1.
Two single locus variants (ST-44 and ST-27) derived from the pri-
mary founder (ST-19). ST-106 and ST-369 are descendents of ST-27,
and double locus variants of the primary founder. The diameter of
the circles is proportional to the number of strains.
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strains were identiﬁed. This suggests a potential risk of
failure for intrapartum antibiotic prophylaxis with b-lactams
for S. agalactiae in the near future. Moreover, 19% of the
S. agalactiae isolates were resistant to erythromycin and 53%
of these were resistant to clindamycin, which comprise be
second-line choices of antibiotic. In respect of erythromycin
resistance among colonizing strains of S. agalactiae, our
results were similar to those described in France and Canada
(18%) [7,8], but differed considerably from the 3.8%
reported in Czech Republic [4] and 38–41.9% in the USA
[9,25]. Together with social determinants and differences of
health care structures, the factors most frequently associated
with these large discrepancies in antimicrobial resistance are
the consumption and inappropriate use of antibiotics [26]. In
Portugal, no signiﬁcant change in the consumption of macro-
lide antibiotics was registered during the period 1997–2006
[27]. However, the uptake of intermediate and long-acting
macrolides (clarithromycin and azithromycin, respectively)
increased signiﬁcantly during this period, and these agents
potentially enhance resistance selection compared to short-
acting macrolides (e.g. erythromycin) [27].
In the present study, macrolide resistance was found to
be predominantly the result of ribosomal methylation (18 of
the 19 resistant strains). Indeed, only one strain displayed
the M phenotype, as conﬁrmed by the presence of the mefA
gene. The prevalence of iMLSB and cMLSB phenotypes was
similar (eight and ten strains, respectively); however, one
strain with the iMLSB mechanism was not associated with
either the mef or the erm genes, suggesting that it could be
related to point mutations in the ribosomal L4 and L22 pro-
teins preventing antibiotic binding, as suggested by Diner
et al. [28]. The mefA gene has been shown to be mobile in a
variety of Gram positive bacteria [29] and its low frequency
among our isolates of S. agalactiae is surprising. Indeed, con-
sidering the remarkable differences in the microﬂora of
diverse anatomic sites (e.g. genital vs. respiratory tract), dis-
similar horizontal gene transfer events are expected to
occur, leading to diverse antibiotic resistance spread. The
study of these phenomena will be important for understand-
ing how macrolide resistance is evolving.
In agreement with previous studies [8,16], the data
obtained in the present study demonstrate that erythromy-
cin resistance was more frequent among genotype III strains
(13/19; 68%); this could comprise a major public health con-
cern because this genotype is also associated with invasive
infections [12]. Curiously, S. agalactiae cps molecular charac-
terization showed that 92.3% (12/13) of these strains
belonged to the subtype III-1. Although MLST analysis
revealed the existence of ﬁve genetic lineages within this
subtype population, all belonged to the same clonal complex,
which originated through the diversiﬁcation of the founding
sequence type (ST-19). These results suggest the genetic
clustering of a macrolide-resistant clone family within the
capsular subtype III-1 population. Indeed, the only available
data worldwide, along with those obtained by ourselves, also
showed the clonal spread of macrolide-resistant S. agalactiae
strains, despite the involvement of a different genotype (V/
ST-1) [30]. To our knowledge, these two studies comprise
the only data available correlating macrolide resistance and
MLST.
In conclusion, the present study demonstrates the higher
prevalence of S. agalactiae genotypes III and V among Portu-
guese women of reproductive age. We also found an impor-
tant association between macrolide resistance and the
subtype III-1/ST-19 clonal complex, where the MLSB pheno-
type was the most frequent. Knowledge of the local distribu-
tion of capsular genotypes and MLST lineages is crucial for
the development of an effective vaccine against S. agalactiae.
This could be an attractive alternative to the intrapartum
antibiotic prophylaxis, which may soon be of limited value
owing to the emergence of antibiotic-resistant strains.
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